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Background
Oal immunotherapy (OIT) may reduce the risk for severe
allergic reaction at accidental ingestion of peanut. We
aimed at developing a peanut OIT protocol with home-
based dose escalations for 6-18 year-old children with
moderate to severe allergic reaction in a double-blind pla-
cebo-controlled challenge (DBPCFC).
Methods
Our pirmary outcome was the increase in the amount of
ingested peanut protein tolerated in DBPCFC by peanut
OIT. Secondarily we investigated safety of OIT. Since Sep-
tember 2011, peanut-sensitized patients with moderate to
severe allergic reaction (1) in DBPCFC were included.
Bronchial hyperreactivity, exhaled nitric oxide, and food
allergy related quality of life (2, 3) were evaluated pre and
post OIT. Roasted and defatted peanut flour, allergenity of
which was assessed using microarray inhibition, was
mixed with margarine (no milk or soy) in 3 concentrations
at hospital kitchen. A teaspoonful of peanut-margarine
mixture weight 1.7 g. From week 20 and on, we used real
peanuts. The first dose of 0.1 mg peanut protein was taken
at hospital and the same dose continued daily at home.
Dose escalations occurred at home every 1 to 2 weeks.
The patient returned to the hospital 7 times for dose esca-
lation. Antihistamine was taken daily until 2 weeks from
reaching the maintenance dose of 4 peanuts. As safety
procedures, exercise was forbidden one hour post each
dose and the day of escalation, and the patients carried
adrenalin auto-injectors.
Results
In November 2012, 18 patients mean age 9 (6-16) y
have entered the OIT. At DBPCFC, the median dose of
peanut protein causing moderate to severe allergic reac-
tion was 55 mg (1/4 peanut), range 5 to 255 mg, 10/18
had received 1 to 3 doses of adrenalin as treatment for
anaphylactic reaction at challenge. The median (range)
serum peanut specific-IgE was 89 (1.8-817) kU/L and
peanut skin prick test was 10 (6-16). Fourteen children
had asthma. Two patients discontinued the study; one
was non-compliant and one had continuous nausea.
One patient has received adrenalin after dose escalation
at home; 2 patients have taken antihistamines once due
to urticaria. Mild oro-pharyngeal itching requiring no
medication was common.
Conclusion
Based on our preliminary results it seems possible to
develop a peanut OIT protocol with home-based dose
escalations also in anaphylactic patients.
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